Status:
RECRUITING
Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Conditions:
Cystic Fibrosis
Eligibility:
All Genders
18-99 years
Brief Summary
The goal of this observational study is to learn about the effects of a specific cystic fibrosis therapy (Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy) on chronic sinonasal di...
Detailed Description
The goal of this study is to characterize the effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy on the sinonasal microbial communities and inflammatory profiles in adult...
Eligibility Criteria
Inclusion
- Subjects between the ages of 18 years old (inclusive) and 99 years old (inclusive)
- English-speaking
- Diagnosed with CF as established by genetic testing combined with clinical assessment and/or sweat chloride
- Patients being seen at the New Hampshire Cystic Fibrosis Center
- Adults able to sign informed consent
Exclusion
- Adults unable to consent
- Individuals who are not yet adults
- Prisoners
Key Trial Info
Start Date :
November 8 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05982795
Start Date
November 8 2023
End Date
December 1 2026
Last Update
December 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756